Designing a First-in-Human Study of an Autologous CRISPR-Edited Hematopoietic Cell Therapy in Severe Sickle Cell Disease: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis
A gene-edited cell therapy cannot be given in ascending doses to healthy volunteers: collection, conditioning, and engraftment make the intervention irreversible, and the dose that matters is the one that restores blood formation. This article develops the scientific and regulatory rationale and a complete protocol synopsis for a hypothetical first-in-human study of an autologous CD34-positive hematopoietic cell product edited ex vivo with CRISPR-Cas9 at an erythroid-specific enhancer to raise fetal hemoglobin in adults with severe sickle cell disease. It proposes an open-label, single-arm study of about 12 participants at three transplant centers, enrolled sequentially after safety and engraftment review of the first participant, with a single infusion at a minimum of 3 million viable edited CD34-positive cells per kilogram as a planning assumption. Primary endpoints are safety and hematopoietic recovery through Month 12, with fetal hemoglobin, edited-cell persistence, and severe vaso-occlusive crisis frequency as secondary and exploratory measures, followed by risk-based long-term surveillance that FDA guidance suggests may extend to 15 years. The article explains why dose escalation is not used and why exposure is measured by engraftment and persistence and not by plasma concentration.Keywords: first-in-human; gene editing; CRISPR-Cas9; sickle cell disease; autologous cell therapy; fetal hemoglobin; long-term follow-up; Phase 1 protocol
Authors
- Dorcas Koomson
- Peivand Pirouzi
- Gloria Anthonia Amoateng Agyemang
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426426
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00